- Home
- CSBR vs HURA Comparison
CSBR vs HURA Comparison
Compare CSBR & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- HURA
- Stock Information
- Founded
- CSBR 1985
- HURA 2009
- Country
- CSBR United States
- HURA United States
- Employees
- CSBR N/A
- HURA N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- HURA
- Sector
- CSBR Health Care
- HURA
- Exchange
- CSBR Nasdaq
- HURA Nasdaq
- Market Cap
- CSBR 111.4M
- HURA 103.3M
- IPO Year
- CSBR 1986
- HURA N/A
- Fundamental
- Price
- CSBR $8.33
- HURA $2.34
- Analyst Decision
- CSBR Strong Buy
- HURA Strong Buy
- Analyst Count
- CSBR 1
- HURA 2
- Target Price
- CSBR $12.00
- HURA $11.50
- AVG Volume (30 Days)
- CSBR 39.6K
- HURA 476.5K
- Earning Date
- CSBR 09-10-2025
- HURA 08-15-2025
- Dividend Yield
- CSBR N/A
- HURA N/A
- EPS Growth
- CSBR N/A
- HURA N/A
- EPS
- CSBR 0.46
- HURA N/A
- Revenue
- CSBR $58,591,000.00
- HURA N/A
- Revenue This Year
- CSBR $15.11
- HURA N/A
- Revenue Next Year
- CSBR $7.80
- HURA $69.15
- P/E Ratio
- CSBR $17.71
- HURA N/A
- Revenue Growth
- CSBR 19.03
- HURA N/A
- 52 Week Low
- CSBR $3.60
- HURA $1.80
- 52 Week High
- CSBR $11.99
- HURA $10.49
- Technical
- Relative Strength Index (RSI)
- CSBR 64.00
- HURA N/A
- Support Level
- CSBR $7.16
- HURA N/A
- Resistance Level
- CSBR $9.63
- HURA N/A
- Average True Range (ATR)
- CSBR 0.64
- HURA 0.00
- MACD
- CSBR 0.11
- HURA 0.00
- Stochastic Oscillator
- CSBR 69.06
- HURA 0.00
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.